Population versus Personalized Medicine in the Clinical Management of CV Disease
|
|
- Jonah Pearson
- 5 years ago
- Views:
Transcription
1 Population versus Personalized Medicine in the Clinical Management of CV Disease Discussion Regarding Individualized Approaches to the Management of CV Risk Robert M. Honigberg, MD Key Questions Do management strategies and treatment goals developed from population based studies lead to appropriate guidelines and care of individual patients? Where is the greatest opportunity for individualization related to cardiovascular risk risk assessment or LDL management? 1
2 Should we treat the line or the dot? y = x R² = LDL-P (nmol/l) LDL-C (mg/dl) Compared current JNC-7 guidelines with individualized guidelines for blood pressure management to calculate risk reduction from expected from treatment Used ARIC study to perform person-specific analysis with longitudinal data Individualized management could prevent the same number of MIs and strokes as JNC-7 at a savings of 67% or Individualized management could prevent 43% more heart attacks and strokes for the same cost as treatment according to JNC-7 guidelines Ann Intern Med. 2011;154:
3 Agenda Residual cardiovascular risk NCEP ATP Guidelines Risk assessment LDL management Review of key literature MESA, Framingham LDL variability Diabetes and metabolic disease Apo B variability Therapy Health economic model Incidence of CHD and Cholesterol Framingham Heart Study Indicates that Measuring Cholesterol Does Not Tell Us Enough The two distribution curves for CHD and no CHD have 80% overlap of total cholesterol (TC) ( mg/dl) 35% of CHD occurs in people with TC<200 Twice as many individuals with TC<200 had CHD than those with TC>300 Castelli et al. Atherosclerosis 124 Supp (1996) S1-S9 From Framingham Heart Study, at 26 years follow-up 3
4 40 Residual Cardiovascular Risk in Major Statin Trials CHD events occur in patients treated with statins Patients Experiencing Major CHD Events, % S 1 LIPID 2 CARE 3 HPS 4 WOSCOPS 5 AFCAPS/ TexCAPS 6 N LDL -35% -25% -28% -29% -26% -25% Secondary High Risk Primary Placebo Statin S Group. Lancet. 1994;344: LIPID Study Group. N Engl J Med. 1998;339: Sacks FM, et al. N Engl J Med. 1996;335: HPS Collaborative Group. Lancet. 2002;360: Shepherd J, et al. N Engl J Med. 1995;333: Downs JR, et al. JAMA. 1998;279: Residual CVD Risk in Patients Treated With Intensive Statin Therapy Patients Experiencing Major CVD Events, % 8 40 Statistically significant, but clinically inadequate CVD reduction N LDL-C,* mg/dl Standard statin therapy Intensive high-dose statin therapy PROVE IT-TIMI 22 2 IDEAL 3 TNT *Mean or median LDL-C after treatment Superko HR. Br J Cardiol. 2006;13: Cannon CP, et al. N Engl J Med. 2004;350: Pedersen TR, et al. JAMA. 2005;294: LaRosa JC, et al. N Engl J Med. 2005;352:
5 Registry Evidence of Residual CVD Risk Among 136,905 hospitalizations for acute CAD events; lipids w/in 24 hrs of admit (at 541 hospitals) Over 50% of CHD patients had LDL-C <100 and 17.6% had LDL-C <70 For patients without h/o CHD, 72.1% had LDL-C <130 and 41.5% had LDL<100 Sachdeva A, et al. Am Heart J 2009; 157:111-7.e2. From AHA s Get with The Guidelines (GWTG) CAD Program and Database; NCEP ATP III: Determining LDL-C Goals Presence of CHD, DM 2 major CV risk factors* Yes No Yes No 10-year CHD risk: FRS Yes No High-Risk: <100mg/dL, optional <70mg/dL >20% 10-20% <10% High-Risk: <100mg/dL Mod-high Risk: <130mg/dL, optional <100mg/dL Moderate risk <130mg/dL Lower risk <160mg/dL 5
6 Improve Risk Assessment Opportunities for Improvement? Multivariable Risk Assessment High Risk CHD/CHD Risk Equiv. (>20% 10-year risk)** NCEP ATP III Approach Treatment Assessment & Goal LDL Management Lifestyle/statin/other If above goal LDL-C < 100 Improve LDL Management Intermediate Risk 2+ Risk Factors* (10-20% 10-year risk)** Treatment Assessment & Goal LDL-C < 130 Low Risk 0-1 Risk Factor* (0-10% 10 year risk)** Treatment Assessment & Goal LDL-C < 160 *Risk factors are age (>45M;>55W), smoking, hypertension, low HDL-C, family history **10-year risk given by age, gender, TC, HDL-C, SBP/hypertension, and smoking (Framingham Risk Score) Issues to be addressed by ATP IV CVD risk assessment More stringent targets versus a fixed dose strategy adjusting dose to risk hs-crp Alternative treatment targets: Role of advanced lipoprotein testing Apo B, LDL-P, non-hdl-c Direct targeting of HDL-C and triglycerides Role of fibrates, niacin, ezetimibe Role of imaging of subclinical atherosclerosis 6
7 NHLBI Integrated Cardiovascular Risk Reduction Guidelines Release of integrated guidelines for: Cholesterol Guideline Update (ATP IV) Hypertension Guideline Update (JNC 8) Obesity Guideline Update (Obesity 2) Also developing new guidelines for: Risk assessment Lifestyle Three major questions in ATP IV What evidence supports LDL-C goals for primary prevention? For secondary prevention? For optimal statin management? What evidence supports LDL-C goals for primary prevention? 7
8 For more information or to check status: Improve Risk Assessment Opportunities for Improvement? Multivariable Risk Assessment High Risk CHD/CHD Risk Equiv. (>20% 10-year risk)** NCEP ATP III Approach Treatment Assessment & Goal LDL Management Lifestyle/statin/other If above goal LDL-C < 100 Improve LDL Management Intermediate Risk 2+ Risk Factors* (10-20% 10-year risk)** Treatment Assessment & Goal LDL-C < 130 Low Risk 0-1 Risk Factor* (0-10% 10 year risk)** Treatment Assessment & Goal LDL-C < 160 *Risk factors are age (>45M;>55W), smoking, hypertension, low HDL-C, family history **10-year risk given by age, gender, TC, HDL-C, SBP/hypertension, and smoking (Framingham Risk Score) 8
9 Recommendations from the NLA Expert Panel on Clinical Utility of Inflammatory Markers and Advanced Lipoprotein Testing Measurement for On-Treatment Management Decisions Davidson, et al. J Clin Lipidol 2011;5: Measures of LDL are not always equal LDL-P measure different from LDL-C LDL-P measures the number of particles LDL-C measures cholesterol content Apo B POLAR SURFACE COAT Phospholipid Free cholesterol NONPOLAR LIPID CORE Cholesteryl Ester Triglyceride 9
10 LDL C can vary with particle size At the same LDL cholesterol, more small LDL vs. large LDL particles present Up to 70% More Particles 100 mg/dl 100 mg/dl Large LDL Small LDL Cholesterol Balance Otvos JD et al. Am J Cardiol 2002;90(suppl):22i-29i Cromwell WC et al. J Clin Lipidology. 2007;1(6): Insulin resistance & LDL-C variability Cholesterol content varies with disease & metabolic state Normal Cholesterol Content Lower Cholesterol Content 100 mg/dl 100 mg/dl Cholesterol Triglycerides Clin Cardiol 1999; 22(6 Suppl): Cholesterol Balance TG enriched particle Cholesterol (ester) exchanged for TG via CETP 10
11 Atherogenic Dyslipidemia of Insulin Resistance Framingham Offspring Study LDL Particles (nmol/l) LDL Particles LDL Cholesterol LDL Particles LDL Cholesterol LDL Cholesterol (mg/dl) HDL Cholesterol (mg/dl) Triglycerides (mg/dl) Cromwell WC and Otvos JD. Curr Athero Reports 2004;6: High LDL Particle Number Drives Atherogenic Plaque Formation A gradient driven process, LDL particles invade the arterial wall and set in motion the cascade of events that leads to atherosclerosis 1,2 1. Fredrickson et al. NEJM 1967; 276: Brunzell, et al. Diabetes Care. 2008;4: Ip et al. Ann Intern Med. 2009;150: After adjustment for LDL-P concentration, particle subclass and size don t impact outcomes 3 11
12 Recommendations from the NLA Expert Panel on Clinical Utility of Inflammatory Markers and Advanced Lipoprotein Testing Measurement for On-Treatment Management Decisions Davidson, et al. J Clin Lipidol 2011;5: Comparative Literature is Population-based* Study CHD Status Atherosclerotic Endpoint LDL-P Associations Stronger? Women s Health Study Circulation 2009; 119: Primary Prevention Incident MI, CHD death, CVA YES VA-HIT Circulation 2006;113: Secondary Prevention Non- fatal MI or CHD Death YES MESA Atherosclerosis 2007;192: Primary Prevention Carotid IMT; CVD Event YES Framingham Heart Study J Clin Lipidology 2007;1: Primary Prevention Incident CVD Events YES EPIC-Norfolk Atherosclerosis 2007;49: Primary Prevention Incident CAD Events YES Cardiovascular Health Study ATVB 2002; 22: Primary Prevention Incident MI or Angina YES PLAC-I Am J Cardiol 2002;90: Secondary Prevention Angiographic MLD YES Healthy Women Study Am J Cardiol 2002;90(suppl):71-77i. Primary Prevention EBCT Coronary Calcium Score YES *Over 330 NMR-based publications in the peer reviewed literature 12
13 Principles for determining appropriate LDL testing guided by landmark publication Value of the new reference test is best examined in cases of disagreement (discordance) between the new and standard tests. Clinical consequences of disagreements between new and standard test requires a fair umpire test. Fair umpire tests include clinical events or disease progression. Glasziou P et al. Ann Intern Med 2008;149: Multi-Ethnic Study of Atherosclerosis (MESA) Large NHLBI observational study of the pathogenesis and progression of subclinical atherosclerosis Subjects include 6,814 asymptomatic men and women free of cardiovascular disease at entry Population consists of 38% White, 28% African-American, 22% Hispanic, and 12% Asian (of Chinese descent) Outcomes in Current Study Carotid IMT of participants not exposed to lipid medications (n=4499) 319 CVD events (MI, CHD death, angina, stroke, stroke death, or other atherosclerotic or CVD death) during 5.5-yr follow-up (n=5598) Otvos et al. J Clin Lipidol 2011;5:
14 Discordance Between LDL-C and LDL-P LDL-P Consistently Tracks Better with Incident CV Events in Discordant Patients Cumulative CV Incidence LDL-P > LDL-C Concordant LDL-P < LDL-C LDL-C underestimates LDL-attributable risk LDL-C overestimates LDL-attributable risk LDL-C mg/dl LDL-P nmol/l 12.5 events/1000 person years 24% increase 10.1 events/1000 person years 27% decrease 7.3 events/1000 Person years Follow-up (years) Otvos et al. J Clin Lipidol 2011;5:
15 MESA: Characteristics by LDL Discordance Subgroups Bad Discordance LDL-P > LDL-C Concordant LDL-P LDL-C Good Discordance LDL-P < LDL-C Diabetes (%) 17 a 11 7 a Waist (cm) 99 a a SBP (mmhg) 127 b Glucose (mg/dl) 109 a a HOMA-insulin resistance 2.2 a a TG (mg/dl) 161 a a HDL-C (mg/dl) 44 a a Values are adjusted for age, sex, and race; a p<0.0001; b p<0.01; c p<0.05 vs concordant subgroup Framingham Offspring Study Long-running NIH/NHLBI observational study of residents of Framingham MA to determine risk factors for future CVD Blood samples were obtained in (exam 4). Lipoprotein particles were measured by NMR spectroscopy and lipids by traditional chemical methods CVD occurrence was monitored during 15-year followup There were 431 CVD events (MI, stroke, CHD death, angina, congestive heart failure) among 3,066 subjects Freedman DS et al., Clin Chem 2004;50: Kathiresan S et al., Circulation 2006;113:20-29 Cromwell W et al., J Clin Lipidol 2007;1:
16 DF4 CHD Event Associations of LDL-P vs LDL-C Framingham Offspring Study Cromwell WC et al. J Clin Lipidol 2007;1(6): Framingham Offspring CVD Event Rates Differences between quartiles within LDL-P 16
17 Slide 31 DF4 eliminate white "Discordant" lines in graph and from the legend Elimate build David Frey, 5/9/2012
18 Example in actual payer population LDL-P distribution at LDL-C<100 mg/dl, N= % Concordant 67% Discordant Number of Subjects LDL-P Concentrations (nmol/l) < >2000 Coronary Heart Disease ICD-9: , ,412, , 414.0,414.07, 414.2, 414.8, 414.9, 429.2, Diabetes Mellitus ICD-9: Hyperlipidemia ICD-9: , Peripheral Arterial Disease ICD-9: , , Symptomatic Carotid Artery Disease ICD-9: , , LDL-P Discordance in Metabolic Syndrome Metabolic syndrome patients in Framingham Study (n=1138) N=286 N=407 N=355 N=233 N=113 N=30 LDL-C (mg/dl) LDL-C LDL-P MetSyn (-) MetSyn (+) LDL-P (nmol/l) From Framingham Offspring Study Circulation 2006;113:
19 LDL Particle Number Distribution in T2DM Subjects Percent of Subjects % (n=19) 5 th 20 th 50 th 80 th percentile 24% (n=364) 43% (n=631) 21% (n=307) 25% 75% 11% (n=163) LDL-C mg/dl (n=1,484) % (n=147) (nmol/l) 43% (n=377) 30% (n=260) 9% (n=76) 2% (n=15) Percent of Subjects 10 40% LDL-C < 70 mg/dl 5 (n=871) (nmol/l) Cromwell WC, Otvos JD. Am J Cardiol 2006;98: ADA/ACC Consensus Statement ApoB or LDL particle number also appear to be more discriminating measures of the adequacy of LDL lowering therapy than are LDL cholesterol or non-hdl cholesterol. *ADA has included LDL particle measurement in 2013 Standards of Medical Care 18
20 2013 AACE Algorithms for Diabetes LDL-P Distribution in T2DM Subjects, LDL-C<50 mg/dl 8% Concordant (LDL-P<500 nmol/l and Non-HDL-C<80 mg/dl) (% of Subjects) <2nd 8% (n=95) 20% (n=250) (N= 1,242) 5th 20th 50th 80th 47% 21% 4% (n=588) (n=258) (n=43) 25% 0.1% (n=8) 500 Malave et al. Am J Cardiol (nmol/l) 19
21 Clinical Implications for LDL Management Improve Risk Assessment Multivariable Risk Assessment High Risk CHD/CHD Risk Equiv. (>20% 10-year risk)** Current ATPIII Approach Treatment Assessment & Goal LDL Management Lifestyle/statin/other If above goal LDL-C < 100 Improve LDL Management 56.5% discordance* Reclassify Risk Using New/Different Variables Intermediate Risk 2+ Risk Factors* (10-20% 10-year risk)** Low Risk 0-1 Risk Factor* (0-10% 10 year risk)** Treatment Assessment & Goal Treatment Assessment & Goal LDL-C < 130 LDL-C < 160 LDL-P > > % discordance* LDL-P > >1300 *from MESA *Risk factors are age (>45M;>55W), smoking, hypertension, low HDL-C, family history **10-year risk given by age, gender, TC, HDL-C, SBP/hypertension, and smoking (Framingham Risk Score) To assess comparability of apo B and LDL-P in association with clinical outcomes 85 clinical outcomes in 25 clinical studies Only apo B statistically significant, LDL-P not significant Only LDL-P statistically significant, apo B not significant Both statistically significant Neither statistically significant The level of statistical significance, as indicated by the P value, and the strength of association, as indicated by the OR, RR, and HR, was more often higher for LDL-P than it was for apo B Clinical Chemistry February 2013;59:
22 Discordance Rate Between LDL-P and apo B? The discordance rate was 29.2% In most cases, LDL-P was a stronger predictor than apo B Discordance rates between LDL-P and apob in various subgroups: - Prediction of CVD or events = 21.1% - Presence of carotid atherosclerosis = 29% - Association with diabetes mellitus = 12.5% Clinical Chemistry 2013;59:1-19 Strengths with the NMR Method The NMR measurement of LDL-P appears to be generally more precise than that of apo B Between-run precision, apo B CV s ranging from 5% to 11% Whereas the same measure for LDL-P was from 2% to 4% NMR LipoProfile is a well-standardized, reagentless test, monitored by FDA central lab & regional devices Apo B is reagent-based immunoassay, with WHO criteria for standardization but no way to enforce the standards NMR provides more information with the analysis than does the single measurement of apo B LDL-P by NMR is more specific for LDL-related risk and does not include other apo B associated lipoproteins with shorter half-lives Clinical Chemistry 2013;59:
23 How can LDL-P help manage heart disease? Guide therapy intervention to reduce the number of cardiovascular events Fine tuning medical therapy Avoiding costly hospitalizations and procedures Self-insured employers becoming interested in using LDL-P within disease management programs Can more directly address medication non-adherence LDL-P can be more useful in identifying metabolic patients that are non-adherent Treatments Change LDL-C and LDL-P Differentially Cholesterol per particle decreases with: Statins Statin + Ezetimibe or Bile Acid Sequestrants Estrogen Replacement Therapy Anti-retrovirals (some) Low fat, High carb diet Therapy LDL-C More Than LDL-P Cholesterol per particle increases with: Fibrates Niacin Pioglitazone Omega 3 FAs Exercise Mediterranean and low carb diet Therapy LDL-P More Than LDL-C Cromwell WC. In: Clinical Challenges in Lipid Disorders.Toth PP, Sica DA, editors. Oxford: Clinical Publishing; 2008.p
24 Adapted from Rosenson et al. Atherosclerosis. 2010; 213:1-7. Appropriate Patient Selection Criteria for LDL-P Clinical use of LDL-P is appropriate within the following patient populations being managed with a lipid-lowering therapy or intensive lifestyle management with one of the following criteria: Known cardiovascular disease (CVD); or CHD risk equivalents such as Type II Diabetes Mellitus, Chronic Kidney Disease (CKD); or Multiple cardio-metabolic risk factors that define the Metabolic Syndrome High Blood pressure or on anti-hypertensive medication High blood sugar High triglycerides Low HDL-C Abdominal obesity 23
25 Medical Policy and Reimbursement for CPT Medicare -covers CPT Medicaid - covers CPT (can vary per state) Tricare - covers CPT WellPoint/Anthem - retired policy, reimburses CPT United Healthcare - retired policy, reimburses CPT Coventry - retired policy, reimburses CPT BCBS of Alabama covers CPT with ICD-9 restrictions BCBS of North Carolina - reimburses CPT CareFirst Blue Cross - reimburses CPT Magna Care - reimburses CPT BCBS of Florida- retired policy, reimburses CPT Regence Blue - retired policy, reimburses CPT Premera - retired policy, reimburses CPT Harvard Pilgrim - reimburses CPT (for diabetes) BCBS of Louisiana - retired policy, reimburses CPT BCBS of Delaware - retired policy, reimburses CPT Health economic model of LDL management Adaptation from health economic model under review 24
26 Health Economic Model for LDL Management Purpose: To assess the cost-effectiveness and health system effects of management to different LDL goals LDL-C & LDL-P combination vs. LDL-C alone Publication also compares LDL-P alone to LDL-C alone Baseline Model has a 3-year time horizon Results reported for years 1 through 3 Based on a hypothetical cohort of 1,000 or 100,000 patients All inputs are based on published literature and referenced in the interactive model Model represents both the payer and the self-insured employer perspectives Cost-Effectiveness Analysis Economic analysis comparing relative costs and outcomes of two or more strategies Formula: Costs LDL-C & LDL-P Costs LDLC Effects LDL-C Effects LD-C & LDL-P Incremental cost effectiveness ratio (ICER) The cost to avoid one additional CVD event with new strategy compared to old Less than $50,000 = cost effective $50,000-$100,000 = border line More than $100,000 = not cost effective 25
27 Health System Effects: Budget Impact Analysis Cardiovascular events Difference in the number of CVD events between 2 strategies Reduction in heart attack and stroke Costs LDL-C & LDL-P Costs LDLC Cost-savings Cost-savings associated with difference in CVD events Costs of heart attack (fatal and non-fatal) and stroke, years 1-3 Costs of testing and additional drug therapy Hypothesis Cost-savings related to avoidance of CVD events outweigh the additional cost of testing, treating (and more people alive and healthy) Additional cost-savings in model for employers From avoiding indirect costs related to productivity Absenteeism, quality of life, and presenteeism while at work Derived from the number of Quality Adjusted Life Years (QALYs) gained Model flow 26
28 Total covered lives at elevated risk Results Incremental cost-effectiveness ratio (ICER) 27
29 Results cumulative number of CVD events avoided Results underlying budget impact Costs of combo Budget Item Cost of lipid alone 22.2 mm MI (fatal & nonfatal) 30.6 mm 28.8 mm Stroke 39.5 mm 8.8 mm Angina 12.1 mm 1.3 mm Other CVD 1.7 mm mm Testing/Treatment 80.2 mm 162 mm Total cost over 3 years mm - saving costs - saving lives 28
30 Results increased worker productivity and quality of life Concluding Remarks As quality of care and individual patient outcomes become more important in terms of health care and reimbursement, practitioners must have the appropriate data to optimally treat individual patients rather than the population as a whole. This is demonstrated today in the case of LDL-lowering therapy and hypertension. Only through subgroup analyses do these differences become apparent. Individualized approaches to LDL management can be cost-effective and reduce the overall budget impact through the avoidance of cardiovascular events 29
31 Compared current JNC-7 guidelines with individualized guidelines for blood pressure management Used ARIC study to perform person-specific analysis with longitudinal data Individualized guidelines can prevent the same number of MIs and strokes as JNC-7 at a savings of 67% or Individualized guidelines can prevent 43% more heart attacks and strokes for the same cost as treatment according to JNC-7 guidelines Archimedes will proactively assess JNC-8 and ATP IV Ann Intern Med. 2011;154: Opportunity to individually manage patients with insulin resistance Prevent under-treatment of CVD risk y = x R² = LDL-P (nmol/l) LDL-C (mg/dl) 30
32 Q&A 31
Review of guidelines for management of dyslipidemia in diabetic patients
2012 international Conference on Diabetes and metabolism (ICDM) Review of guidelines for management of dyslipidemia in diabetic patients Nan Hee Kim, MD, PhD Department of Internal Medicine, Korea University
More information10/15/2012. Lessons Learned from Tim Russert: Investigating Residual Risk. Tim Russert: Residual CV Risk?
Lessons Learned from Tim Russert: Investigating Residual Risk Peter H. Jones, MD, FACP Associate Professor Methodist DeBakey Heart and Vascular Center Baylor College of Medicine Houston, Texas Tim Russert:
More informationNicole Ciffone, MS, ANP-C, AACC Clinical Lipid Specialist
1 Nicole Ciffone, MS, ANP-C, AACC Clinical Lipid Specialist New Cardiovascular Horizons Multidisciplinary Strategies for Optimal Cardiovascular Care February 7, 2015 2 Objectives After participating in
More informationATP IV: Predicting Guideline Updates
Disclosures ATP IV: Predicting Guideline Updates Daniel M. Riche, Pharm.D., BCPS, CDE Speaker s Bureau Merck Janssen Boehringer-Ingelheim Learning Objectives Describe at least two evidence-based recommendations
More informationLipids, Lipoproteins and Cardiovascular Risk: Getting the Most out of New and Old Biomarkers. New and Old Biomarkers. Disclosures
Lipids, Lipoproteins and Cardiovascular Risk: Getting the Most out of New and Old Biomarkers William Cromwell, MD, FAHA, FNLA Diplomate, American Board of Clinical Lipidology Chief Lipoprotein and Metabolic
More informationBest Lipid Treatments
Best Lipid Treatments Pam R. Taub MD, FACC Director of Step Family Cardiac Rehabilitation and Wellness Center Associate Professor of Medicine UC San Diego Health System Overview of Talk Review of pathogenesis
More informationCase Presentation. Rafael Bitzur The Bert W Strassburger Lipid Center Sheba Medical Center Tel Hashomer
Case Presentation Rafael Bitzur The Bert W Strassburger Lipid Center Sheba Medical Center Tel Hashomer Case Presentation 50 YO man NSTEMI treated with PCI 1 month ago Medical History: Obesity: BMI 32,
More informationApproach to Dyslipidemia among diabetic patients
Approach to Dyslipidemia among diabetic patients Farzad Hadaegh, MD, Professor of Internal Medicine & Endocrinology Prevention of Metabolic Disorders Research Center, Research Institute for Endocrine Sciences
More information1. Which one of the following patients does not need to be screened for hyperlipidemia:
Questions: 1. Which one of the following patients does not need to be screened for hyperlipidemia: a) Diabetes mellitus b) Hypertension c) Family history of premature coronary disease (first degree relatives:
More informationDavid Y. Gaitonde, MD, FACP Endocrinology DDEAMC, Fort Gordon
David Y. Gaitonde, MD, FACP Endocrinology DDEAMC, Fort Gordon I have no actual or potential conflicts of interest in relation to this program or presentation. Raphael School of Athens, 1509-1511 Apply
More informationJoslin Diabetes Center Advances in Diabetes and Thyroid Disease 2013 Consensus and Controversy in Diabetic Dyslipidemia
Consensus and Controversy in Diabetes and Dyslipidemia Om P. Ganda MD Director, Lipid Clinic Joslin diabetes Center Boston, MA, USA CVD Outcomes in DM vs non- DM 102 Prospective studies; 698, 782 people,
More informationHow would you manage Ms. Gold
How would you manage Ms. Gold 32 yo Asian woman with dyslipidemia Current medications: Simvastatin 20mg QD Most recent lipid profile: TC = 246, TG = 100, LDL = 176, HDL = 50 What about Mr. Williams? 56
More informationHow to Reduce Residual Risk in Primary Prevention
How to Reduce Residual Risk in Primary Prevention Helene Glassberg, MD Assistant Professor of Medicine Section of Cardiology Hospital of the University of Pennsylvania Philadelphia, PA USA Patients with
More informationDyslipidemia in the light of Current Guidelines - Do we change our Practice?
Dyslipidemia in the light of Current Guidelines - Do we change our Practice? Dato Dr. David Chew Soon Ping Senior Consultant Cardiologist Institut Jantung Negara Atherosclerotic Cardiovascular Disease
More informationLipoprotein Particle Profile
Lipoprotein Particle Profile 50% of people at risk for HEART DISEASE are not identified by routine testing. Why is LPP Testing The Most Comprehensive Risk Assessment? u Provides much more accurate cardiovascular
More informationJUPITER NEJM Poll. Panel Discussion: Literature that Should Have an Impact on our Practice: The JUPITER Study
Panel Discussion: Literature that Should Have an Impact on our Practice: The Study Kaiser COAST 11 th Annual Conference Maui, August 2009 Robert Blumberg, MD, FACC Ralph Brindis, MD, MPH, FACC Primary
More informationThe JUPITER trial: What does it tell us? Alice Y.Y. Cheng, MD, FRCPC January 24, 2009
The JUPITER trial: What does it tell us? Alice Y.Y. Cheng, MD, FRCPC January 24, 2009 Learning Objectives 1. Understand the role of statin therapy in the primary and secondary prevention of stroke 2. Explain
More information2013 ACC AHA LIPID GUIDELINE JAY S. FONTE, MD
2013 ACC AHA LIPID GUIDELINE JAY S. FONTE, MD How do you interpret my blood test results? What are our targets for these tests? Before the ACC/AHA Lipid Guidelines A1c:
More informationHyperlipidemia: Lowering the Bar on the Lipid Limbo. Community Faculty Development Symposium March 13, 2004 Hugh Huizenga MD, MPH
Mark slides Hyperlipidemia: Lowering the Bar on the Lipid Limbo Community Faculty Development Symposium March 13, 2004 Hugh Huizenga MD, MPH Hyperlipidemia is a common problem Nearly 50% of men in the
More informationLIPOPROTEIN PROFILING
LIPOPROTEIN PROFILING in CLINICAL DIAGNOSTICS and LIFE SCIENCE RESEARCH Product Information, March 2015 2004-2015, numares HEALTH LIPOPROTEINS AND CARDIOVASCULAR DISEASE High blood cholesterol is a well-known
More informationLDL cholesterol and cardiovascular outcomes?
LDL cholesterol and cardiovascular outcomes? Prof Kausik Ray, BSc (hons), MBChB, FRCP, MD, MPhil (Cantab), FACC, FESC Professor of Cardiovascular Disease Prevention St Georges University of London Honorary
More informationLatest Guidelines for Lipid Management
Latest Guidelines for Lipid Management Goals Recognize the differences between different guidelines Understand the effective strategies to tailor lipid lowering therapies based on evidence and guideline
More informationPlacebo-Controlled Statin Trials
PREVENTION OF CHD WITH LIPID MANAGEMENT AND ASPIRIN: MATCHING TREATMENT TO RISK Robert B. Baron MD MS Professor and Associate Dean UCSF School of Medicine Declaration of full disclosure: No conflict of
More informationAndrew Cohen, MD and Neil S. Skolnik, MD INTRODUCTION
2 Hyperlipidemia Andrew Cohen, MD and Neil S. Skolnik, MD CONTENTS INTRODUCTION RISK CATEGORIES AND TARGET LDL-CHOLESTEROL TREATMENT OF LDL-CHOLESTEROL SPECIAL CONSIDERATIONS OLDER AND YOUNGER ADULTS ADDITIONAL
More informationLipid Management C. Samuel Ledford, MD Interventional Cardiology Chattanooga Heart Institute
Lipid Management 2018 C. Samuel Ledford, MD Interventional Cardiology Chattanooga Heart Institute Disclosures No Financial Disclosures Disclosures I am an Interventional Cardiologist I put STENTS in for
More informationAmerican Osteopathic College of Occupational and Preventive Medicine 2012 Mid-Year Educational Conference St. Petersburg, Florida
The 21 st Century Paradigm Shift: Prevention Rather Than Intervention for the Treatment of Stable CHD The Economic Burden of Cardiovascular Diseases Basil Margolis MD, FACC, FRCP Director, Preventive Cardiology
More informationCVD Risk Assessment. Lipid Management in Women: Lessons Learned. Conflict of Interest Disclosure
Lipid Management in Women: Lessons Learned Conflict of Interest Disclosure Emma A. Meagher, MD has no conflicts to disclose Emma A. Meagher, MD Associate Professor, Medicine and Pharmacology University
More informationDyslipidemia and the Use of Statins. Troy L Randle, DO, FACC, FACOI
Dyslipidemia and the Use of Statins Troy L Randle, DO, FACC, FACOI Objective: Identify CV risk. Determine what dyslipidemia (dyslipoproteinemia) is Decrease CV risk and optimize lipid levels for your
More informationCurrent Cholesterol Guidelines and Treatment of Residual Risk COPYRIGHT. J. Peter Oettgen, MD
Current Cholesterol Guidelines and Treatment of Residual Risk J. Peter Oettgen, MD Associate Professor of Medicine Harvard Medical School Director, Preventive Cardiology Beth Israel Deaconess Medical Center
More informationWhat Else Do You Need to Know? Presenter Disclosure Information. Case 1: Cardiovascular Risk Assessment in a 53-Year-Old Man. Learning Objectives
9: 1:am Understanding Dyslipidemia Testing and Screening: Importance of Lipoprotein Particle Analysis SPEAKER Matthew Sorrentino, MD, FACC Presenter Disclosure Information The following relationships exist
More informationCardiovascular Complications of Diabetes
VBWG Cardiovascular Complications of Diabetes Nicola Abate, M.D., F.N.L.A. Professor and Chief Division of Endocrinology and Metabolism The University of Texas Medical Branch Galveston, Texas Coronary
More informationPCSK9 Inhibitors and Modulators
PCSK9 Inhibitors and Modulators Pam R. Taub MD, FACC Director of Step Family Cardiac Rehabilitation and Wellness Center Associate Professor of Medicine UC San Diego Health System Disclosures Speaker s
More informationDyslipidemia: Lots of Good Evidence, Less Good Interpretation.
Dyslipidemia: Lots of Good Evidence, Less Good Interpretation. G Michael Allan Evidence & CPD Program, ACFP Associate Professor, Dept of Family, U of A. CFPC CoI Templates: Slide 1 Faculty/Presenter Disclosure
More informationInflammation and and Heart Heart Disease in Women Inflammation and Heart Disease
Inflammation and Heart Disease in Women Inflammation and Heart Disease What is the link between een inflammation and atherosclerotic disease? What is the role of biomarkers in predicting cardiovascular
More informationCase # 278 Should lipoprotein cholesterol assays disappear?
Case # 278 Should lipoprotein cholesterol assays disappear? Let's get into the case: I was contacted by a provider who states: "I have a 70 year old guy with absolutely no cardiac risk factors except for
More informationCVD risk assessment using risk scores in primary and secondary prevention
CVD risk assessment using risk scores in primary and secondary prevention Raul D. Santos MD, PhD Heart Institute-InCor University of Sao Paulo Brazil Disclosure Honoraria for consulting and speaker activities
More informationDyslipidaemia. Is there any new information? Dr. A.R.M. Saifuddin Ekram
Dyslipidaemia Is there any new information? Dr. A.R.M. Saifuddin Ekram PhD,FACP,FCPS(Medicine) Professor(c.c.) & Head Department of Medicine Rajshahi Medical College Rajshahi-6000 New features of ATP III
More informationTreating Lipids for Prevention of CAD in Women: Matching Therapy to Risk
TREATING LIPIDS FOR PREVENTION OF CAD IN WOMEN: MATCHING THERAPY TO RISK Robert B. Baron MD MS Professor and Associate Dean UCSF School of Medicine Declaration of full disclosure: No conflict of interest
More informationAtherosclerotic Disease Risk Score
Atherosclerotic Disease Risk Score Kavita Sharma, MD, FACC Diplomate, American Board of Clinical Lipidology Director of Prevention, Cardiac Rehabilitation and the Lipid Management Clinics September 16,
More informationThere are many ways to lower triglycerides in humans: Which are the most relevant for pancreatitis and for CV risk?
There are many ways to lower triglycerides in humans: Which are the most relevant for pancreatitis and for CV risk? Michael Davidson M.D. FACC, Diplomate of the American Board of Lipidology Professor,
More informationFasting or non fasting?
Vascular harmony Robert Chilton Professor of Medicine University of Texas Health Science Center Director of Cardiac Catheterization labs Director of clinical proteomics Which is best to measure Lower continues
More informationAssessing Cardiovascular Risk to Optimally Stratify Low- and Moderate- Risk Patients. Copyright. Not for Sale or Commercial Distribution
CLINICAL Viewpoint Assessing Cardiovascular Risk to Optimally Stratify Low- and Moderate- Risk Patients Copyright Not for Sale or Commercial Distribution By Ruth McPherson, MD, PhD, FRCPC Unauthorised
More informationLandmark Clinical Trials.
Landmark Clinical Trials 1 Learning Objectives Discuss clinical trials and their role in lipid and lipoprotein treatment in cardiovascular prevention. Review the clinical trials of lipid-altering drug
More information4/7/ The stats on heart disease. + Deaths & Age-Adjusted Death Rates for
+ Update on Lipid Management Stacey Gardiner, MD Assistant Professor Division of Cardiovascular Medicine Medical College of Wisconsin + The stats on heart disease Over the past 10 years for which statistics
More informationUpdate On Diabetic Dyslipidemia: Who Should Be Treated With A Fibrate After ACCORD-LIPID?
Update On Diabetic Dyslipidemia: Who Should Be Treated With A Fibrate After ACCORD-LIPID? Karen Aspry, MD, MS, ABCL, FACC Assistant Clinical Professor of Medicine Warren Alpert Medical School of Brown
More informationIntroduction. Objective. Critical Questions Addressed
Introduction Objective To provide a strong evidence-based foundation for the treatment of cholesterol for the primary and secondary prevention of ASCVD in women and men Critical Questions Addressed CQ1:
More informationPREVENTION OF CARDIOVASCULAR DISEASE IN WOMEN
PREVENTION OF CARDIOVASCULAR DISEASE IN WOMEN Robert B. Baron MD MS Professor and Associate Dean UCSF School of Medicine Declaration of full disclosure: No conflict of interest EXPLAINING THE DECREASE
More informationMarshall Tulloch-Reid, MD, MPhil, DSc, FACE Epidemiology Research Unit Tropical Medicine Research Institute The University of the West Indies, Mona,
Marshall Tulloch-Reid, MD, MPhil, DSc, FACE Epidemiology Research Unit Tropical Medicine Research Institute The University of the West Indies, Mona, Jamaica At the end of this presentation the participant
More informationThe Diabetes Link to Heart Disease
The Diabetes Link to Heart Disease Anthony Abe DeSantis, MD September 18, 2015 University of WA Division of Metabolism, Endocrinology and Nutrition Oswald Toosweet Case #1 68 yo M with T2DM Diagnosed DM
More informationEstablished Risk Factors for Coronary Heart Disease (CHD)
Getting Patients to Make Small Lifestyle Changes That Result in SIGNIFICANT Improvements in Health - Prevention of Diabetes and Obesity for Better Health Maureen E. Mays, MD, MS, FACC Director ~ Portland
More informationGuidelines for Management of Dyslipidemia and Prevention of Cardiovascular Disease
AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AMERICAN COLLEGE OF ENDOCRINOLOGY Guidelines for Management of Dyslipidemia and Prevention of Cardiovascular Disease Writing Committee Chair: Paul S. Jellinger,
More informationPREDIABETES TESTING SERVICES
PREDIABETES TESTING SERVICES ASSESSING DIABETES RISK IN ASYMPTOMATIC ADULTS Depending upon population characteristics, up to 70% of individuals with prediabetes will ultimately progress to diabetes at
More informationPrevention of Heart Disease: The New Guidelines
Prevention of Heart Disease: The New Guidelines Nisha I. Parikh MD MPH Assistant Professor of Medicine Division of Cardiology Department of Medicine University of California San Francisco May 18 th 2015
More information9/18/2017 DISCLOSURES. Consultant: RubiconMD. Research: Amgen, NHLBI OUTLINE OBJECTIVES. Review current CV risk assessment tools.
UW MEDICINE UW MEDICINE UCSF ASIAN TITLE HEALTH OR EVENT SYMPOSIUM 2017 DISCLOSURES Consultant: RubiconMD ESTIMATING CV RISK IN ASIAN AMERICANS AND PREVENTION OF CVD Research: Amgen, NHLBI EUGENE YANG,
More informationThe New Gold Standard for Lipoprotein Analysis. Advanced Testing for Cardiovascular Risk
The New Gold Standard for Lipoprotein Analysis Advanced Testing for Cardiovascular Risk Evolution of Lipoprotein Testing The Lipid Panel Total Cholesterol = VLDL + LDL + HDL Evolution of Lipoprotein Testing
More informationThe TNT Trial Is It Time to Shift Our Goals in Clinical
The TNT Trial Is It Time to Shift Our Goals in Clinical Angioplasty Summit Luncheon Symposium Korea Assoc Prof David Colquhoun 29 April 2005 University of Queensland, Wesley Hospital, Brisbane, Australia
More informationDisclosures. Prevention of Heart Disease: The New Guidelines. Summary of Talk. Four guidelines. No relevant disclosures.
Disclosures Prevention of Heart Disease: The New Guidelines No relevant disclosures Nisha I. Parikh MD MPH Assistant Professor of Medicine Division of Cardiology Department of Medicine University of California
More information2013 Cholesterol Guidelines. Anna Broz MSN, RN, CNP, AACC Adult Certified Nurse Practitioner North Ohio Heart, Inc.
2013 Cholesterol Guidelines Anna Broz MSN, RN, CNP, AACC Adult Certified Nurse Practitioner North Ohio Heart, Inc. Disclosures Speaker Gilead Sciences NHLBI Charge to the Expert Panel Evaluate higher quality
More informationPharmaceutical Help to Control Cholesterol
Pharmaceutical Help to Control Cholesterol Catherine E. Cooke, PharmD, BCPS, PAHM President, PosiHealth, Inc. Clinical Associate Professor, Univ. of Maryland This program has been brought to you by PharmCon
More informationLifetime clinical and economic benefits of statin-based LDL lowering in the 20-year Followup of the West of Scotland Coronary Prevention Study
Lifetime clinical and economic benefits of statin-based LDL lowering in the 20-year Followup of the West of Scotland Coronary Prevention Study Harvey White Green Lane Cardiovascular Service and Cardiovascular
More informationContemporary management of Dyslipidemia
Contemporary management of Dyslipidemia Todd Anderson Feb 2018 Disclosure Statement Within the past two years: I have not had an affiliation (financial or otherwise) with a commercial organization that
More informationThe Clinical Unmet need in the patient with Diabetes and ACS
The Clinical Unmet need in the patient with Diabetes and ACS Professor Kausik Ray (UK) BSc(hons), MBChB, MD, MPhil, FRCP (lon), FRCP (ed), FACC, FESC, FAHA Diabetes is a global public health challenge
More informationHighlights of the new blood pressure and cholesterol guidelines: A whole new philosophy. Jeremy L. Johnson, PharmD, BCACP, CDE, BC-ADM
Highlights of the new blood pressure and cholesterol guidelines: A whole new philosophy Jeremy L. Johnson, PharmD, BCACP, CDE, BC-ADM OSHP 2014 Annual Meeting Oklahoma City, OK April 4, 2014 1 Objectives
More informationCVD Risk Assessment. Michal Vrablík Charles University, Prague Czech Republic
CVD Risk Assessment Michal Vrablík Charles University, Prague Czech Republic What is Risk? A cumulative probability of an event, usually expressed as percentage e.g.: 5 CV events in 00 pts = 5% risk This
More informationLow-density lipoprotein as the key factor in atherogenesis too high, too long, or both
Low-density lipoprotein as the key factor in atherogenesis too high, too long, or both Lluís Masana Vascular Medicine and Metabolism Unit. Sant Joan University Hospital. IISPV. CIBERDEM Rovira i Virgili
More informationPreventing Cardiovascular Disease With Lipid Management: Matching Therapy to Risk
PREVENTING CARDIOVASCULAR DISEASE WITH LIPID MANAGEMENT : MATCHING TREATMENT TO RISK Robert B. Baron MD MS Professor and Associate Dean UCSF School of Medicine Declaration of full disclosure: No conflict
More informationLessons from Recent Atherosclerosis Trials
Lessons from Recent Atherosclerosis Trials Han, Ki Hoon MD PhD Asan Medical Center Seoul, Korea Change of concept Primary vs. secondary prevention Low risk vs. High risk High Risk CHD and equivalents CHD
More informationPlacebo-Controlled Statin Trials MANAGEMENT OF HIGH BLOOD CHOLESTEROL MANAGEMENT OF HIGH BLOOD CHOLESTEROL: IMPLICATIONS OF THE NEW GUIDELINES
MANAGEMENT OF HIGH BLOOD CHOLESTEROL: IMPLICATIONS OF THE NEW GUIDELINES Robert B. Baron MD MS Professor and Associate Dean UCSF School of Medicine Declaration of full disclosure: No conflict of interest
More informationLipid Risk Factors (Novel) in Risk Assessment and Management of Cardiovascular Disease
Lipid Risk Factors (Novel) in Risk Assessment and Management of Cardiovascular Disease Policy Number: Original Effective Date: MM.02.013 02/01/2009 Line(s) of Business: Current Effective Date: HMO; PPO;
More informationWhat have We Learned in Dyslipidemia Management Since the Publication of the 2013 ACC/AHA Guideline?
What have We Learned in Dyslipidemia Management Since the Publication of the 2013 ACC/AHA Guideline? Salim S. Virani, MD, PhD, FACC, FAHA Associate Professor, Section of Cardiovascular Research Baylor
More informationDescription of Discordance Between LDL Cholesterol, Non-HDL Cholesterol, and LDL Particle Number Among Patients of a Lipid Clinic
Volume 8 Number 3 Article 14 9-26-2017 Description of Discordance Between LDL Cholesterol, Non-HDL Cholesterol, and LDL Particle Number Among Patients of a Lipid Clinic Joshua W. Gaborcik The Ohio State
More informationBeyond Framingham: Risk Assessment & Treatment for Primary Prevention
Beyond Framingham: Risk Assessment & Treatment for Primary Prevention Ronald M. Goldenberg, MD, FRCPC, FACE Consultant Endocrinologist, North York General Hospital Medical Co-Director, LMC Endocrinology
More informationLipid Therapy: Statins and Beyond. Ivan Anderson, MD RIHVH Cardiology
Lipid Therapy: Statins and Beyond Ivan Anderson, MD RIHVH Cardiology Outline The cholesterol hypothesis and lipid metabolism The Guidelines 4 Groups that Benefit from Lipid therapy Initiation and monitoring
More informationPreclinical Detection of CAD: Is it worth the effort? Michael H. Crawford, MD
Preclinical Detection of CAD: Is it worth the effort? Michael H. Crawford, MD 1 Preclinical? No symptoms No physical findings No diagnostic ECG findings No chest X-ray X findings No diagnostic events 2
More information2013 Lipid Guidelines Practical Approach. Edward Goldenberg, MD FACC,FACP, FNLA Medical Director of Cardiovascular Prevention CCHS
2013 Lipid Guidelines Practical Approach Edward Goldenberg, MD FACC,FACP, FNLA Medical Director of Cardiovascular Prevention CCHS EVIDENCE BASED MEDICINE Case #1 - LB 42 yo Asian/American female who was
More informationJanet B. Long, MSN, ACNP, CLS, FAHA, FNLA Rhode Island Cardiology Center
Primary and Secondary Prevention of Coronary Artery Disease: What is the role of non statin drugs (fenofibrates, fish oil, niacin, folate and vitamins)? Janet B. Long, MSN, ACNP, CLS, FAHA, FNLA Rhode
More informationUpdate on Dyslipidemia and Recent Data on Treating the Statin Intolerant Patient
Update on Dyslipidemia and Recent Data on Treating the Statin Intolerant Patient Steven E. Nissen MD Chairman, Department of Cardiovascular Medicine Cleveland Clinic Disclosure Consulting: Many pharmaceutical
More informationNew Guidelines in Dyslipidemia Management
The Third IAS-OSLA Course on Lipid Metabolism and Cardiovascular Risk Muscat, Oman, February 2017 New Guidelines in Dyslipidemia Management Dr. Khalid Al-Waili, MD, FRCPC, DABCL Senior Consultant Medical
More informationTargeting Lipids Strategies for Patients with Cardiometabolic Risk
Targeting Lipids Strategies for Patients with Cardiometabolic Risk Faculty Disclosure David G. Carmouche, MD Director, Center for Cardiovascular Disease Prevention Baton Rouge Clinic ASH Specialist in
More informationAccelerated atherosclerosis begins years prior to the diagnosis of diabetes
Joslin Diabetes Forum 211: Optimizing Care for the Practicing Clinician Risk for atherosclerosis is 2 4 times greater in patients with diabetes CVD accounts for 65% of diabetic mortality >5% of patients
More informationDisclosures. Background 1 What is Known MENOPAUSE, ESTROGENS, AND LIPOPROTEIN PARTICLES. Background 2 What is Not Known 10/2/2017
Disclosures MENOPAUSE, ESTROGENS, AND LIPOPROTEIN PARTICLES Grants: NIH, Quest Diagnostics Consultant: Quest Diagnostics Merck Global Atherosclerosis Advisory Board Ronald M. Krauss, Children s Hospital
More informationA: Epidemiology update. Evidence that LDL-C and CRP identify different high-risk groups
A: Epidemiology update Evidence that LDL-C and CRP identify different high-risk groups Women (n = 27,939; mean age 54.7 years) who were free of symptomatic cardiovascular (CV) disease at baseline were
More informationUnderstanding Cardiometabolic RiskL Strategies for Prevention and Management
Page 1 Cardiometabolic Risk: Management & Prevention Michael W. Ravotti DHSc, PA-C ACCL, Clinical Lipid Specialist Director of Graduate Medical Education Conemaugh Health System Johnstown PA This program
More informationBehind LDL: The Metabolism of ApoB, the Essential Apolipoprotein in LDL and VLDL
Behind LDL: The Metabolism of ApoB, the Essential Apolipoprotein in LDL and VLDL Sung-Joon Lee, PhD Division of Food Science Institute of Biomedical Science and Safety Korea University Composition of Lipoproteins:
More informationYoung high risk patients the role of statins Dr. Mohamed Jeilan
Young high risk patients the role of statins Dr. Mohamed Jeilan KCS Congress: Impact through collaboration CONTACT: Tel. +254 735 833 803 Email: kcardiacs@gmail.com Web: www.kenyacardiacs.org Disclosures
More informationNo relevant financial relationships
MANAGEMENT OF LIPID DISORDERS Balancing Benefits and harms Disclosure Robert B. Baron, MD MS Professor and Associate Dean UCSF School of Medicine No relevant financial relationships baron@medicine.ucsf.edu
More informationInsulin resistance: targeting dyslipidemia beyond the LDL-cholesterol. Disclosures: Presentation outline
Insulin resistance: targeting dyslipidemia beyond the LDL-cholesterol Rocky Mountain Metabolic Syndrome Symposium May 14 th 21 Mori Krantz MD FACC Associate Professor, University of Colorado Director of
More informationPdf. TC = 152 TG = 170 HDL-C = 37 VLDL-C = 34 LDL-C = 81 Non-HDL-C = 115 TC/HDL-C = 4.1 TG/HDL-C = 4.6. I was asked for my thoughts.
Pdf LIPID CASE 252 Particle Core Composition Hi Lipidaholics: The following case demonstrates a topic I have wanted to discuss in depth. It illustrates the concept of particle composition meaning what
More informationJohn J.P. Kastelein MD PhD Professor of Medicine Dept. of Vascular Medicine Academic Medial Center / University of Amsterdam
Latest Insights from the JUPITER Study John J.P. Kastelein MD PhD Professor of Medicine Dept. of Vascular Medicine Academic Medial Center / University of Amsterdam Inflammation, hscrp, and Vascular Prevention
More informationAn update on lipidology and cardiovascular risk management. Lipids, Metabolism & Vascular Risk Section - Royal Society of Medicine
An update on lipidology and cardiovascular risk management Lipids, Metabolism & Vascular Risk Section - Royal Society of Medicine National and international lipid modification guidelines: A critical appraisal
More informationPlacebo-Controlled Statin Trials EXPLAINING THE DECREASE IN DEATHS FROM CHD! PREVENTION OF CARDIOVASCULAR DISEASE IN WOMEN EXPLAINING THE DECREASE IN
PREVENTION OF CARDIOVASCULAR DISEASE IN WOMEN Robert B. Baron MD MS Professor and Associate Dean UCSF School of Medicine Declaration of full disclosure: No conflict of interest EXPLAINING THE DECREASE
More informationSubclinical atherosclerosis in CVD: Risk stratification & management Raul Santos, MD
Subclinical atherosclerosis in CVD: Risk stratification & management Raul Santos, MD Sao Paulo Medical School Sao Paolo, Brazil Subclinical atherosclerosis in CVD risk: Stratification & management Prof.
More informationImplementation of CV Risk and. Dyslipidemia Guidelines. Impact on Americans 11/25/2014. Summary Implementing new. Dyslipidemia Guidelines
Summary Implementing new Dyslipidemia Guidelines Implementation of CV Risk and Dyslipidemia Guidelines Ronald D. Scott, MD Regional KPSC CVD Co-Lead Family Medicine and Lipidology, WLA ASCVD (Atherosclerotic
More informationCurrent Challenges in CardioMetabolic Testing. Kenneth French, Director of Clinical Operations
Current Challenges in CardioMetabolic Testing Kenneth French, Director of Clinical Operations Disclosers Employee at VAP Diagnostics Laboratory Outline Cardiometabolic Disease: Current Challenges and Methodology
More informationCopyright 2017 by Sea Courses Inc.
Diabetes and Lipids Copyright 2017 by Sea Courses Inc. All rights reserved. No part of this document may be reproduced, copied, stored, or transmitted in any form or by any means graphic, electronic, or
More informationAssessing atherosclerotic risk for long term preventive treatment
Assessing atherosclerotic risk for long term preventive treatment Donald A. Smith, MD, MPH Endocrinologist, Clinical Lipidologist Associate Professor of Medicine and Preventive Medicine Icahn School of
More informationMacrovascular Residual Risk. What risk remains after LDL-C management and intensive therapy?
Macrovascular Residual Risk What risk remains after LDL-C management and intensive therapy? Defining Residual Vascular Risk The risk of macrovascular events and microvascular complications which persists
More informationDiabetic Dyslipidemia
Diabetic Dyslipidemia Dr R V S N Sarma, M.D., (Internal Medicine), M.Sc., (Canada), Consultant Physician Cardiovascular disease (CVD) is a significant cause of illness, disability, and death among individuals
More informationComprehensive Treatment for Dyslipidemias. Eric L. Pacini, MD Oregon Cardiology 2012 Cardiovascular Symposium
Comprehensive Treatment for Dyslipidemias Eric L. Pacini, MD Oregon Cardiology 2012 Cardiovascular Symposium Primary Prevention 41 y/o healthy male No Medications Normal BP, Glucose and BMI Social History:
More informationWhen Statins Aren t Enough: Appropriate Therapies for High-Risk Patients with Diabetes
When Statins Aren t Enough: Appropriate Therapies for High-Risk Patients with Diabetes Kim K. Birtcher, MS, PharmD, AACC, FNLA, CLS, BCPS (AQ-Cardiology), CDE Clinical Professor University of Houston College
More information